Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.

Guiseppe IndolfiDeirdre KellyGabriella NebbiaRaffaele IorioAnna ManiaVania GiacometLeszek SzenbornJiang ShaoMun Sang YueChia-Hsiang HsuehBandita ParhyKathryn KerseyAlessandra MangiaMalgorzata PawlowskaSanjay Bansal

Published in: Hepatology (Baltimore, Md.) (2022)

The pangenotypic regimen of sofosbuvir-velpatasvir-voxilaprevir is highly efficacious and well-tolerated in treating chronic HCV infection in adolescents.

Keyphrases

hepatitis c virus
young adults
human immunodeficiency virus
physical activity
hiv infected
drug induced